Targeting Genetic Changes in IDH-Mutant Gliomas with a Novel Use of an FDA-Approved Drug
Search text
About 24 results
(0.07 seconds)
The tumor microenvironment (TME) is a complex system containing multiple cell types and cytokines that control cancer cell growth and promote cancer immune evasion. · Developing drugs to treat other brain tumors and other types of cancer. TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.
When applied to immune cells, this enzyme inhibitor enhanced dendritic proliferation and drove T cell differentiation away from immunosuppressive regulatory T cells and towards cytotoxic T cells. · Induces anticancer immune response. This novel enzyme inhibitor is a promising immunotherapy target that promotes antitumor immune response and increases tumor control when used with a tumor vaccine.
One type of immunotherapy at the forefront of the field is the use of chimeric antigen receptor (CAR) T cells to genetically redirect T cells to tumor targets. Using virally-mediated genetic reprogramming may be key to creating metabolically robust CAR T cells for use in solid tumor immunotherapy. To reap the benefits that this treatment has yielded for hematologic malignancies, CAR T cells will need to be more metabolically durable in order to perform in the microenvironment of solid tumors.